Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IBIO iBio Inc
- Stocks
- Healthcare
- NYSEAMERICAN: IBIO
Price (delayed)
$0.7995
Market cap
$13.21M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.31
Enterprise value
$12.35M
iBio is a global leader in plant-based biologics manufacturing. Its FastPharming® System combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and
Highlights
The EPS has soared by 94% YoY and by 54% from the previous quarter
IBIO's debt has plunged by 76% YoY and by 9% from the previous quarter
The company's net income rose by 9% YoY but it fell by 9% QoQ
The company's equity has shrunk by 54% YoY and by 18% QoQ
IBIO's quick ratio is down by 38% from the previous quarter
Key stats
What are the main financial stats of IBIO
Market
Valuations
Earnings
Shares outstanding
16.52M
Market cap
$13.21M
Enterprise value
$12.35M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.69
Price to sales (P/S)
21.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.92
Revenue
$375,000
Gross profit
$375,000
Operating income
-$16.81M
Net income
-$20.99M
EBIT
-$20.76M
EBITDA
-$19.64M
Free cash flow
-$15.7M
Per share
Balance sheet
Liquidity
EPS
-$0.31
EPS diluted
-$0.31
Free cash flow per share
-$1.59
Book value per share
$1.15
Revenue per share
$0.04
TBVPS
$1.32
Total assets
$19.1M
Total liabilities
$7.72M
Debt
$4.32M
Equity
$11.38M
Working capital
$663,000
Debt to equity
0.38
Current ratio
1.12
Quick ratio
0.96
Net debt/EBITDA
0.04
Margins
Efficiency
Dividend
EBITDA margin
-5,237.9%
Gross margin
100%
Net margin
-5,597.9%
Operating margin
-4,483.5%
Return on assets
-89.3%
Return on equity
-130.5%
Return on invested capital
-244.9%
Return on capital employed
-151.5%
Return on sales
-5,537.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IBIO stock price
How has the iBio stock price performed over time
Intraday
9.82%
1 week
3.39%
1 month
-18.41%
1 year
-55.83%
YTD
-67.37%
QTD
-80.11%
Financial performance
How have iBio's revenue and profit performed over time
Revenue
$375,000
Gross profit
$375,000
Operating income
-$16.81M
Net income
-$20.99M
Gross margin
100%
Net margin
-5,597.9%
IBIO's net margin has soared by 88% YoY but it is down by 9% from the previous quarter
The company's operating margin has surged by 88% YoY but it fell by 8% QoQ
The company's net income rose by 9% YoY but it fell by 9% QoQ
The operating income has declined by 8% since the previous quarter but it has increased by 8% year-on-year
Price vs fundamentals
How does IBIO's price correlate with its fundamentals
Growth
What is iBio's growth rate over time
Valuation
What is iBio stock price valuation
P/E
N/A
P/B
0.69
P/S
21.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.92
The EPS has soared by 94% YoY and by 54% from the previous quarter
IBIO's price to book (P/B) is 65% lower than its last 4 quarters average of 1.8 and 61% lower than its 5-year quarterly average of 1.6
The company's equity has shrunk by 54% YoY and by 18% QoQ
IBIO's price to sales (P/S) is 79% less than its 5-year quarterly average of 93.3 and 75% less than its last 4 quarters average of 77.7
Efficiency
How efficient is iBio business performance
The ROIC has plunged by 173% YoY and by 99% from the previous quarter
The ROS has soared by 88% YoY but it has contracted by 9% from the previous quarter
iBio's return on assets has shrunk by 57% YoY and by 45% QoQ
iBio's return on equity has decreased by 32% QoQ but it has increased by 12% YoY
Dividends
What is IBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IBIO.
Financial health
How did iBio financials performed over time
iBio's total assets is 147% more than its total liabilities
The company's total liabilities has shrunk by 69% YoY
iBio's total assets has plunged by 62% YoY and by 12% from the previous quarter
IBIO's debt is 62% less than its equity
IBIO's debt has plunged by 76% YoY and by 9% from the previous quarter
The company's equity has shrunk by 54% YoY and by 18% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.